| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF01740902 |
| P698 | PubMed publication ID | 8439984 |
| P2093 | author name string | T Wong | |
| S Gandhi | |||
| J Samuel | |||
| J M Nabholtz | |||
| B M Longenecker | |||
| R R Koganty | |||
| M Reddish | |||
| G D MacLean | |||
| M Smolenski | |||
| P2860 | cites work | Signal transduction via leukocyte antigen CD43 (sialophorin). Feedback regulation by protein kinase C | Q68410320 |
| Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11 | Q68865805 | ||
| T and Tn, general carcinoma autoantigens | Q71372455 | ||
| Monoclonal antibody against a cryptic carbohydrate antigen of murine and human lymphocytes. I. Antigen expression in non-cryptic or unsubstituted form on certain murine lymphomas, on a spontaneous murine mammary carcinoma, and on several human adeno | Q72722741 | ||
| Why are proteins O-glycosylated? | Q37951273 | ||
| Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2----6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. | Q38347485 | ||
| Predictive value of lectin binding on breast-cancer recurrence and survival | Q38349289 | ||
| Cell-surface macromolecular and morphological changes related to allotransplantability in the TA3 tumor | Q40146062 | ||
| Morphological and biochemical properties of a new human breast cancer cell line | Q40229605 | ||
| Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene | Q41581624 | ||
| Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. | Q41728009 | ||
| Determination of apical membrane polarity in mammary epithelial cell cultures: The role of cell-cell, cell-substratum, and membrane-cytoskeleton interactions | Q41769437 | ||
| A B72.3 second-generation-monoclonal antibody (CC49) defines the mucin-carried carbohydrate epitope Gal beta(1-3) [NeuAc alpha(2-6)]GalNAc | Q43897415 | ||
| Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA) | Q44149681 | ||
| Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer | Q44572570 | ||
| Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant | Q46140388 | ||
| Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients | Q46260260 | ||
| Ovine submaxillary mucin. Primary structure and peptide substrates of UDP-N-acetylgalactosamine:mucin transferase | Q67576992 | ||
| Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer | Q67718972 | ||
| Tn antigen and UDP-Gal:GalNAc alpha-R beta 1-3Galactosyltransferase expression in human breast carcinoma | Q67911362 | ||
| Active Immunization of Human Ovarian Cancer Patients Against a Common Carcinoma (Thomsen-Friedenreich) Determinant Using a Synthetic Carbohydrate Antigen | Q68145704 | ||
| P433 | issue | 4 | |
| P921 | main subject | breast cancer | Q128581 |
| immunologic adjuvant | Q967453 | ||
| P304 | page(s) | 215-222 | |
| P577 | publication date | 1993-01-01 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant | |
| P478 | volume | 36 |
| Q40497118 | A SCID mouse model for human immune response and disease |
| Q37380026 | A new model for the presentation of tumor-associated antigens and the quest for an anticancer vaccine: a solution to the synthesis challenge via ring-closing metathesis |
| Q74525885 | A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm |
| Q36138929 | A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer |
| Q37100578 | Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma |
| Q37375709 | Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein |
| Q33924634 | Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues |
| Q35525289 | Cancer vaccines and carbohydrate epitopes |
| Q37810597 | Carbohydrate-based vaccines: challenges and opportunities |
| Q73934556 | Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine |
| Q77768655 | Conjugation of 5-azido-3-oxapentyl glycosides with thiolated proteins through the use of thiophilic derivatives |
| Q74410570 | Development and characterization of an antibody directed to an alpha-N-acetyl-D-galactosamine glycosylated MUC2 peptide |
| Q73358382 | Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations |
| Q38828915 | Efficient chemoenzymatic synthesis of sialyl Tn-antigens and derivatives |
| Q41090411 | Human tumor antigens are ready to fly. |
| Q72094408 | Immune Responses of Mice and Human Breast Cancer Patients following Immunization with Synthetic Sialyl‐Tn Conjugated to KLH Plus Detox Adjuvant |
| Q71729275 | Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients |
| Q71729264 | Immunoscintigraphy of colorectal cancer using 111In-labeled monoclonal antibody to mucin |
| Q38353772 | Immunotherapy for the treatment of breast cancer |
| Q36868822 | Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines |
| Q38296152 | Keyhole limpet hemocyanin contains Gal(β1–3)-GalNAc determinants that are cross-reactive with the T antigen |
| Q43554044 | Large-scale production of the carbohydrate portion of the sialyl-Tn epitope, alpha-Neup5Ac-(2-->6)-D-GalpNAc, through bacterial coupling |
| Q50047316 | Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results |
| Q41204090 | Mucin glycoproteins in neoplasia |
| Q37104199 | Nanotechnology in vaccine delivery |
| Q43911246 | Novel Tn antigen-containing neoglycopeptides: synthesis and evaluation as anti tumor vaccines. |
| Q37812128 | Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens |
| Q41710754 | Peptide mimotopes of carbohydrate antigens |
| Q40694541 | Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma |
| Q35584716 | Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer |
| Q77768611 | Polyacrylamide-based glycoconjugates as tools in glycobiology |
| Q35079733 | Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens |
| Q33652622 | Preclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging. |
| Q33588526 | Prospects for the therapeutic use of anticancer vaccines |
| Q40849316 | Protein glycosylation in cancer biology: an overview |
| Q34379303 | Recent advances in the development of breast cancer vaccines |
| Q30814920 | Selection of peptide ligands for the antimucin core antibody C595 using phage display technology: definition of candidate epitopes for a cancer vaccine |
| Q73701468 | Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes |
| Q41125993 | Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer |
| Q35143294 | Strategies in cancer vaccines development |
| Q41285973 | Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides |
| Q37121774 | Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial |
| Q37120643 | Synthetic and immunological studies of 5'-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins |
| Q108768848 | The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans |
| Q33609455 | The immunology and immunotherapy of breast cancer: an update |
| Q33918509 | Toll-like receptor agonists in cancer therapy |
| Q34067537 | Toll-like receptor agonists: are they good adjuvants? |
| Q34719681 | Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice |
Search more.